Trailing-twelve-month (TTM) revenue is $3.05 Billion with a year-over-year growth of +29.41%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $706,300,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $783,800,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-18 |
| Q1 FY2026Period ended 2026-03-31 | $761,700,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $801,700,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $3,053,500,000 |
Current P/S: $9,404,757,436 market capitalization ÷ $3,053,500,000 TTM revenue = 3.08x.
Market capitalization source: FMP quote. Quote observed 2026-09-24T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $801.70M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-25T00:15:56.748Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Drug Delivery | $70M | $87M | $58M | $36M | $39M | $34M |
| International Omnipod | $835M | $1.0B | $1.2B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Non-US | $308M | $360M | $363M | $410M | $523M | $754M |
| UNITED STATES | $596M | $739M | $942M | $1.3B |
$3.05B
$3.05 Billion
+29.41%
vs. $2.36B a year ago (TTM)
+25.13%
5 Year compound annual growth rate
1 Year
+29.41%
3 Year
+27.73%
5 Year
+25.13%
10 Year
+23.98%
15 Year
+24.53%
20 Year
+47.15%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.71B | +$636.50M | +30.73% |
| 2024 | $2.07B | +$374.50M | +22.07% |
| 2023 | $1.70B | +$391.80M | +30.02% |
| 2022 | $1.31B | +$206.50M | +18.79% |
| 2021 | $1.10B | +$194.40M | +21.49% |
| 2020 |
TTM Growth
+29.41%
3-Year CAGR
+27.73%
5-Year CAGR
+25.13%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-25T00:15:56.748Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $2.0B |
| $2.7B |
| $2.0B |
| $904.40M |
| +$166.20M |
| +22.51% |
| 2019 | $738.20M | +$174.38M | +30.93% |
| 2018 | $563.82M | +$100.06M | +21.57% |
| 2017 | $463.77M | +$96.78M | +26.37% |
| 2016 | $366.99M | +$103.10M | +39.07% |
